AbbVie - ABBV Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABBV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABBV, but not buy additional shares or sell existing shares.
View ABBV analyst ratings or view top-rated stocks.

12 analysts have issued twelve-month target prices for AbbVie's shares. Their ABBV share price forecasts range from $135.00 to $200.00. On average, they anticipate the company's stock price to reach $160.27 in the next year. This suggests a possible upside of 10.4% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $161.61 at the start of the year. Since then, ABBV shares have decreased by 10.2% and is now trading at $145.14.
View the best growth stocks for 2023 here.

AbbVie saw a drop in short interest in January. As of January 15th, there was short interest totaling 11,960,000 shares, a drop of 7.5% from the December 31st total of 12,930,000 shares. Based on an average daily volume of 5,560,000 shares, the days-to-cover ratio is presently 2.2 days.
View AbbVie's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our ABBV earnings forecast.

AbbVie will be holding an earnings conference call on Thursday, February 9th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

AbbVie Inc. (NYSE:ABBV) posted its quarterly earnings data on Thursday, October, 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.22 by $0.11. The company had revenue of $14.34 billion for the quarter, compared to analyst estimates of $14.30 billion. AbbVie had a trailing twelve-month return on equity of 155.88% and a net margin of 23.19%. The company's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the firm earned $2.83 EPS.
Read the conference call transcript.

AbbVie declared a quarterly dividend on Friday, October 28th. Investors of record on Friday, January 13th will be given a dividend of $1.48 per share on Wednesday, February 15th. This represents a $5.92 dividend on an annualized basis and a dividend yield of 4.08%. The ex-dividend date is Thursday, January 12th. This is a boost from the stock's previous quarterly dividend of $1.41.
Read our dividend analysis for ABBV.

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 4.08%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 79.04%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 51.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

AbbVie issued an update on its FY22 earnings guidance on Friday, January, 6th. The company provided earnings per share guidance of $13.70-13.74 for the period, compared to the consensus estimate of $13.85.

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a variety of retail and institutional investors. Top institutional investors include Edmp Inc. (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), Envestnet Asset Management Inc. (0.19%), New York State Common Retirement Fund (0.19%), DekaBank Deutsche Girozentrale (0.18%) and Bank of Montreal Can (0.17%). Insiders that own company stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABBV stock can currently be purchased for approximately $145.14.

AbbVie (NYSE:ABBV) has a market capitalization of $256.68 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.49 on an earnings per share basis.

The company employs 50,000 workers across the globe.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.